Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Eur J Echocardiogr ; 10(4): 549-55, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19211568

RESUMO

AIMS: Relationship between obesity and cardiovascular (CV) disease depends not only on the amount of body fat, but also on its distribution. For example, individuals with increased fat accumulation in the abdominal region have atherogenic lipid profiles and are at increased CV risk. The loss of elasticity in medium and large arteries is an early manifestation of atherosclerosis. The aim of this study was to evaluate whether echocardiographic epicardial adipose tissue, an index of cardiac adiposity, is related to carotid stiffness and carotid intima-media thickness (IMT), indexes of subclinical atherosclerosis, better than waist circumference in hypertensive patients. METHODS AND RESULTS: We studied 459 patients with Grade I and II essential hypertension who were referred to our outpatient clinic over a period from May 2007 to March 2008. The population was first sorted by waist circumference and then by epicardial fat < or = 7 or >7 mm. We measured epicardial fat thickness, waist circumference, carotid artery stiffness, and carotid IMT in all patients. Patients divided according to waist circumference showed no statistical differences in carotid artery stiffness between the two groups. Subjects with epicardial fat >7 mm were older, had higher systolic, diastolic, and pulse pressure, increased left ventricular mass index, carotid IMT, diastolic parameters, and stiffness parameters compared with those with epicardial fat < or = 7 mm (P < 0.001). A positive correlation was found between epicardial fat and age, pulse pressure, stiffness parameters, carotid IMT, systolic blood pressure, and duration of hypertension, and a negative correlation was found with diastolic parameters. Age, carotid IMT, and stiffness parameters were independently related to epicardial fat. CONCLUSION: Our findings indicate that epicardial fat reflects carotid artery stiffness in hypertension-induced organ damage.


Assuntos
Tecido Adiposo/diagnóstico por imagem , Doenças das Artérias Carótidas/diagnóstico por imagem , Hipertensão/diagnóstico por imagem , Obesidade/diagnóstico por imagem , Pericárdio/diagnóstico por imagem , Tecido Adiposo/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Pressão Sanguínea , Artérias Carótidas/diagnóstico por imagem , Artérias Carótidas/fisiopatologia , Doenças das Artérias Carótidas/etiologia , Doenças das Artérias Carótidas/fisiopatologia , Ecocardiografia , Ecocardiografia Doppler de Pulso , Feminino , Humanos , Hipertensão/etiologia , Hipertensão/fisiopatologia , Gordura Intra-Abdominal/diagnóstico por imagem , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Obesidade/complicações , Pericárdio/patologia , Fatores de Risco , Circunferência da Cintura , Adulto Jovem
3.
Drugs Aging ; 19(10): 723-32, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12390049

RESUMO

Newer classes of antihypertensive agents, such as angiotensin II receptor antagonists, may offer benefits to patients in addition to their ability to lower blood pressure. It is accepted that chronic hypertension contributes to the development of cerebrovascular and cardiovascular disease, and several studies have demonstrated a link between hypertension and reduced cognitive function, especially in patients not receiving antihypertensive medication. In an initial clinical trial, the angiotensin II receptor antagonist losartan was shown to improve cognitive function in patients with hypertension, including in those who were elderly (up to 73 years of age). This effect cannot be explained by a reduction in blood pressure alone and is likely to involve interactions with the diverse biological actions of the renin-angiotensin system. Improving or maintaining cognitive function in patients with hypertension may translate into economic benefits beyond those expected due to blood pressure control, and would result in considerable quality-of-life benefits for the aging population.


Assuntos
Angiotensina II/metabolismo , Antagonistas de Receptores de Angiotensina , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Transtornos Cognitivos/tratamento farmacológico , Losartan/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Envelhecimento/fisiologia , Inibidores da Enzima Conversora de Angiotensina/farmacocinética , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Animais , Anti-Hipertensivos/farmacocinética , Anti-Hipertensivos/farmacologia , Ensaios Clínicos como Assunto , Transtornos Cognitivos/economia , Transtornos Cognitivos/etiologia , Humanos , Hipertensão/complicações , Hipertensão/tratamento farmacológico , Hipertensão/economia , Losartan/farmacocinética , Losartan/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...